BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:44 AM | Browse: 740 | Download: 2248
 |
Received |
|
2022-05-14 12:41 |
|
Peer-Review Started |
|
2022-05-06 08:27 |
|
First Decision by Editorial Office Director |
|
2022-06-11 04:14 |
|
Return for Revision |
|
2022-06-12 04:55 |
|
Revised |
|
2022-06-26 08:52 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-08-19 03:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-08-21 17:55 |
|
Articles in Press |
|
2022-08-21 17:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-09-02 06:29 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo and Zheng-Xu Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Projects in China |
CLB19J053 |
| Scientific Research Projects in China |
19SWAQ13 |
|
| Corresponding Author |
Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com |
| Key Words |
Stem cell; Meta-analysis; COVID-19; Mesenchymal stem cells |
| Core Tip |
In this study, we investigated whether mesenchymal stem cell (MSC) have therapeutic efficacy in novel coronavirus disease 2019 (COVID-19) patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels and a reduction of D-dimer levels was also not observed in patients after stem cell administration. Interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy. There was a significant improvement in overall survival (OS) after stem cell therapy. Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved. |
| Publish Date |
2022-09-16 11:52 |
| Citation |
Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9714.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9714 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
